Current Report Filing (8-k)
April 15 2019 - 8:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported):
April 12, 2019
AYTU BIOSCIENCE, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
001-38247
|
47-0883144
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
373 Inverness Parkway, Suite 206
Englewood, CO 80112
(Address
of principal executive offices, including Zip Code)
Registrant’s
telephone number, including area code:
(720) 437-6580
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07 Submission of Matters to a Vote of Security
Holders.
The
2019 annual meeting of stockholders for Aytu BioScience, Inc. was
held on April 12, 2019. Of the 12,455,435 shares outstanding on the
record date for the meeting, a total of 9,446,603 shares were
present or represented at the meeting.
The matters voted on
and the results of the votes are as follows:
1.
Our stockholders
elected six members to our board of directors as
follows:
Members
|
|
Number of Votes
Cast Against
|
|
Number of Broker
Non-Votes
|
|
|
|
|
|
Joshua R.
Disbrow
|
5,149,902
|
0
|
235,142
|
4,061,559
|
|
|
|
|
|
Gary V.
Cantrell
|
5,139,275
|
0
|
245,769
|
4,061,559
|
|
|
|
|
|
Carl C.
Dockery
|
5,173,759
|
0
|
211,285
|
4,061,559
|
|
|
|
|
|
John A. Donofrio,
Jr.
|
5,183,997
|
0
|
201,047
|
4,061,559
|
|
|
|
|
|
Michael E.
Macaluso
|
5,140,142
|
0
|
244,902
|
4,061,559
|
|
|
|
|
|
Ketan B.
Mehta
|
5,148,977
|
0
|
236,067
|
4,061,559
|
2.
The “Exchange
Agreement Proposal” described in the Company’s
definitive proxy statement was approved with 5,149,752 votes in
favor, 232,435 votes against and 2,857 abstentions. The number of
broker non-votes was 4,061,559.
3.
The ratification of
the appointment of Plante & Moran, PLLC as the Company’s
independent registered public accounting firm for the fiscal year
ending June 30, 2019 was approved with 9,040,394 votes in favor,
182,903 votes against and 223,306 abstentions.
4.
The proposal to
approve the adjournment of the Annual Meeting, if necessary, to
continue to solicit votes for the Exchange Agreement Proposal was
approved with 8,192,040 votes in favor, 1,159,918 votes against and
94,645 abstentions.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
AYTU
BIOSCIENCE, INC.
|
|
|
|
|
|
|
|
|
|
|
Date:
|
April
15, 2019
|
|
By:
|
/s/
Joshua R. Disbrow
|
|
|
|
|
Joshua
R. Disbrow
|
|
|
|
|
Chief
Executive Officer
|
|
|
|
|
|
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From Mar 2024 to Apr 2024
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From Apr 2023 to Apr 2024